PUMA Antibody

PUMA (p53 upregulated modulator of apoptosis) belongs to pro-apoptotic members of Bcl2 family's BH3-only subgroup, and besides its most critical role as mediator of p53/TP53-dependent/-independent apoptosis, it acts as a regulator of ER stress-induced neuronal apoptosis also. PUMA is expressed ubiquitously and predominately localizes to mitochondria where it execute induction of cytochrome c release. PUMA mediates apoptosis via direct binding with anti-apoptotic members of the Bcl-2 family and is capable of interacting with MCL1, BCL2A1, BCL2 and BCL2L1/BCL-XL. PUMA binding to inhibitory members of Bcl-2 family (Bcl-2-like proteins) leads to Bax and/or Bak displacement mediated activation and formation of pore-like structures over mitochondrial membrane, which permeabilizes the outer mitochondrial membrane, resulting in mitochondrial dysfunction and caspase activation. PUMA is induced by p53, DNA damage, glucocorticoid treatment, deprivation of growth factors etc. and through ER stress in a DDIT3/CHOP-dependent manner. PUMA has been reported to involve in multiple physiological and pathological processes, including immune response, cancer, neurodegenerative diseases and bacterial as well as viral infections.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: IF/IHC, WB.

Showing Publications 1 - 2 of 2.

Publications using NB500-261	Applications	Species
Haider, N, Dutt, P Et al. NEK10 tyrosine phosphorylates p53 and controls its transcriptional activity. Oncogene 2020-07-01 [PMID: 32561851] (IF/IHC, Human)	IF/IHC	Human
Stylianou S, Clarke RB, Brennan K et al. Aberrant activation of notch signaling in human breast cancer. Cancer Res 2006-02-01 [PMID: 16452208] (WB, Human)	WB	Human

Array NB500-261

• PUMA Antibodies
• PUMA ELISA Kits
• PUMA Lysates
• PUMA Proteins